Press release
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma FRIENDSWOOD, Texas, Dec.
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma\nFRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent expert consensus paper titled “31-Gene Expression Profiling for Cutaneous Melanoma: An Expert Consensus Panel,” which endorses the Company’s DecisionDx-Melanoma test. The paper can be viewed here.1 “This consensus translates the robust data supporting DecisionDx-Melanoma into practical direction for clinicians,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “The panel’s unanimous endorsement of DecisionDx-Melanoma underscores its value in supporting informed, personalized care decisions that may help improve outcomes for patients with melanoma.” Authored by a panel of ten melanoma experts from leading academic and clinical institutions, the paper presents evidence-based recommendations supporting DecisionDx-Melanoma as a best-practice tool for guiding management decisions in patients with cutaneous melanoma. The panel concluded that the test provides prognostic information independent of traditional clinicopathologic factors and can be integrated with existing staging systems to improve patient risk assessment and help optimize clinical decision-making. Drawing on a comprehensive review of 26 published studies encompassing more than 7,500 patients, the panel used a modified Delphi process to reach unanimous agreement on nine consensus statements defining the test’s role in risk stratification, sentinel lymph node biopsy (SLNB) decision making and long-term patient management. Key conclusions from the expert panel include the following: DecisionDx-Melanoma demonstrates robust clinical utility and validated performance, supported by high-quality (SORT A) evidence showing accurate and consistent prognostic information for patients with invasive melanoma to help clinicians better assess metastatic risk and guide management across a wide range of disease presentations.DecisionDx-Melanoma can be used across a broad range of tumor stages. Panelists agreed DecisionDx-Melanoma should be used in earlier-stage patients to identify those who may benefit f...